Denise da Gama Jaen Batista, Ludmila Ferreira de Almeida Fiuza, Frédérique Klupsch, Krislayne Nunes da Costa, Marcos Meuser Batista, Ketlym da Conceição, Hassiba Bouafia, Gérard Vergoten, Régis Millet, Xavier Thuru, Christian Bailly, Maria de Nazaré Correia Soeiro
New affordable drugs are needed for the treatment of infection with the protozoan parasite Trypanosoma cruzi responsible for the Chagas disease (CD). Only two old drugs are currently available, nifurtimox and benznidazole (Bz) but they exhibit unwanted side effects and display a weak activity in the late chronic phase of the disease. In this context, we evaluated the activity of a series of aryl-pyrazolone derivatives against T cruzi, using both bloodstream trypomastigote and intracellular amastigote forms of the parasite...
May 15, 2024: Experimental Parasitology